BofA/Merrill Lynch Upgrades Momenta Pharmaceuticals (MNTA) to Neutral
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Underperform to Neutral.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $12.30 yesterday.
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $12.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform
- Agora Inc. (API) PT Raised to $6.80 at BofA Securities
- Capital One beats Q2 EPS by $1.13 as Discover integration gains pace
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
